A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 08 Nov 2017 According to Regeneron Pharmaceuticals media release, this trial was initiated in the third quarter of 2017.
- 08 Nov 2017 Status changed from not yet recruiting to recruiting as per Regeneron Pharmaceuticals media release.
- 19 May 2017 New trial record